[go: up one dir, main page]

DK1255537T3 - Farnesylproteintransferasehæmmere til behandling af brystcancer - Google Patents

Farnesylproteintransferasehæmmere til behandling af brystcancer

Info

Publication number
DK1255537T3
DK1255537T3 DK01905717T DK01905717T DK1255537T3 DK 1255537 T3 DK1255537 T3 DK 1255537T3 DK 01905717 T DK01905717 T DK 01905717T DK 01905717 T DK01905717 T DK 01905717T DK 1255537 T3 DK1255537 T3 DK 1255537T3
Authority
DK
Denmark
Prior art keywords
breast cancer
protein transferase
treatment
transferase inhibitors
farnesyl protein
Prior art date
Application number
DK01905717T
Other languages
Danish (da)
English (en)
Inventor
Peter Albert Palmer
Ivan David Horak
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1255537T3 publication Critical patent/DK1255537T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01905717T 2000-02-04 2001-02-01 Farnesylproteintransferasehæmmere til behandling af brystcancer DK1255537T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04

Publications (1)

Publication Number Publication Date
DK1255537T3 true DK1255537T3 (da) 2006-08-21

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01905717T DK1255537T3 (da) 2000-02-04 2001-02-01 Farnesylproteintransferasehæmmere til behandling af brystcancer

Country Status (13)

Country Link
US (4) US20030027839A1 (fr)
EP (1) EP1255537B1 (fr)
JP (1) JP5491681B2 (fr)
AT (1) ATE323474T1 (fr)
AU (1) AU2001233726A1 (fr)
CA (1) CA2396865C (fr)
CY (1) CY1105477T1 (fr)
DE (1) DE60118889T2 (fr)
DK (1) DK1255537T3 (fr)
ES (1) ES2262626T3 (fr)
PT (1) PT1255537E (fr)
SI (1) SI1255537T1 (fr)
WO (1) WO2001056552A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
MXPA04005207A (es) * 2001-11-30 2004-08-19 Schering Corp Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
CN1917877A (zh) * 2003-11-06 2007-02-21 先灵公司 用于治疗乳癌的法呢基转移酶抑制剂和抗激素药的组合
AR047329A1 (es) 2003-12-12 2006-01-18 Wyeth Corp Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
CA2559221A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007075923A2 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
WO2009151683A2 (fr) * 2008-03-12 2009-12-17 Link Medicine Corporation Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
EP2288195B1 (fr) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Procédé et appareil pour le fonctionnement d'une station de base dans un système de communication sans fil
ME02794B (fr) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle à liaison méthylène
CA2888485C (fr) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle a liaison phenyle
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
AU2016308564B2 (en) 2015-08-17 2018-04-26 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221227B1 (en) * 1995-12-08 2002-08-28 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN1094937C (zh) * 1997-04-25 2002-11-27 詹森药业有限公司 具抑制法呢基转化酶作用的喹唑啉酮类
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6410534B1 (en) * 1998-07-02 2002-06-25 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DK1094839T3 (da) * 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
ATE289602T1 (de) * 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
ID29241A (id) * 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2
WO2001045740A2 (fr) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions et procedes de traitement du cancer du sein
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JP2003525255A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
SI1255537T1 (sl) 2006-10-31
EP1255537A2 (fr) 2002-11-13
PT1255537E (pt) 2006-09-29
US20030027839A1 (en) 2003-02-06
EP1255537B1 (fr) 2006-04-19
JP5491681B2 (ja) 2014-05-14
DE60118889T2 (de) 2006-11-30
CA2396865C (fr) 2009-04-14
DE60118889D1 (de) 2006-05-24
JP2003521509A (ja) 2003-07-15
AU2001233726A1 (en) 2001-08-14
US20110098318A1 (en) 2011-04-28
US20090018164A1 (en) 2009-01-15
WO2001056552A2 (fr) 2001-08-09
US20040192726A1 (en) 2004-09-30
ATE323474T1 (de) 2006-05-15
ES2262626T3 (es) 2006-12-01
CA2396865A1 (fr) 2001-08-09
CY1105477T1 (el) 2010-04-28
WO2001056552A3 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
DK1255537T3 (da) Farnesylproteintransferasehæmmere til behandling af brystcancer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
ATE375794T1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
ATE554087T1 (de) Neue kinaseinhibitoren
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
GB0112348D0 (en) Compounds
DK1339407T3 (da) Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DE60233261D1 (de) Inhibitoren von humanem adam-10
BRPI0308606B8 (pt) compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos
DE60329326D1 (de) Tace inhibitoren
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA03005374A (es) Carbazoles antitumorales.
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE480260T1 (de) Stabile dosierungsform von phenylalanin-derivaten